Betta Pharmaceuticals (300558.SZ) appoints LI MAO as Chief Research and Development Officer and Chief Medical Officer.
Baida Pharmaceutical (300558.SZ) announced that, for the operational needs of the company, upon nomination by the chairman of the board, the fourth board...
Betta Pharmaceuticals (300558.SZ) announced that, due to the needs of the company's management, nominated by the chairman and approved by the second meeting of the Nomination Committee of the Fourth Board of Directors, the board agreed to appoint LI MAO as the Chief Research and Development Officer and Chief Medical Officer of the company. LI MAO will be in charge of the company's new drug research and medical clinical research departments, with a term from the date of board approval to the end of this term of the board of directors.
Related Articles
BOCOM INTL: The possibility of the Fed cutting interest rates only once this year remains, and there is still a scenario where interest rates may not be cut.
Meituan's online catering stores have been upgraded, with the addition of a "made-to-order" information display column.
Morgan Stanley: Maintains "overweight" rating on PICC Group (01339) with a target price of HK$7.6.
BOCOM INTL: The possibility of the Fed cutting interest rates only once this year remains, and there is still a scenario where interest rates may not be cut.
Meituan's online catering stores have been upgraded, with the addition of a "made-to-order" information display column.
Morgan Stanley: Maintains "overweight" rating on PICC Group (01339) with a target price of HK$7.6.
RECOMMEND
Three-Year R&D Spend Drains RMB 2.4 Billion, Urgent Cash Needs Drive Maiwei Biotech Back to Hong Kong Amid Compliance Scrutiny
18/09/2025
Why Generating Profit Remains Challenging for Lidar Companies
18/09/2025
SEC Adopts Landmark Rule to Restrict Shareholder Class Actions in Bid to Revive IPO Market
18/09/2025
